{"id":"W2906546777","doi":"10.1016/j.jval.2018.09.718","title":"PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Empagliflozin; Semaglutide; Lixisenatide; Liraglutide; Medicine; Dulaglutide; Exenatide; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Hazard ratio; Myocardial infarction; Diabetes mellitus; Cardiology; Pharmacology; Endocrinology; Confidence interval; Agonist; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01043904,0.001386057,0.008615048,0.003912537,0.0003458571,0.002597236,0.001261341,0.002129489,0.006714216],"category_scores_gemma":[0.02998515,0.0009126546,0.01742101,0.004139907,0.0009090451,0.00181666,0.001823215,0.001934802,0.0005034416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001784253,"about_ca_system_score_gemma":0.002701472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003876558,"about_ca_topic_score_gemma":0.01056481,"domain_scores_codex":[0.9895467,0.004395024,0.003636289,0.001134092,0.000978144,0.0003097491],"domain_scores_gemma":[0.978964,0.01453821,0.004566062,0.0005017462,0.001189394,0.0002406236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.01733348,0.00008120434,0.005814643,0.5250183,0.4101821,0.0001268742,0.0001536718,0.0002640958,0.0004534479,0.0002871861,0.001055432,0.03922962],"study_design_scores_gemma":[0.009993987,0.001171499,0.01213385,0.04568541,0.9245061,0.0001675738,0.0001381211,0.0001477104,0.00017051,0.000386531,0.00544983,0.00004876991],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01371963,0.9830945,0.0003309555,0.0003581906,0.0002456509,0.0002664591,0.00121332,0.00001400153,0.000757194],"genre_scores_gemma":[0.3251048,0.6666574,0.00182897,0.002447498,0.0005921837,0.0007274279,0.001949647,0.00003155948,0.0006605524],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01043904,"threshold_uncertainty_score":0.05520755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03565310845774038,"score_gpt":0.2958013506025581,"score_spread":0.2601482421448177,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}